A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Inclusion Criteria:

- Participants must have histological or cytological confirmed diagnosis of the
following tumor types that is advanced and/or metastatic cancer and must be, in the
judgment of the investigator, an appropriate participant for experimental therapy

- Part A: Any type of solid tumor ("all comer")

- Part B1: Gastric or Gastroesophageal Junction (GEJ) adenocarcinoma

- Part B2: Hepatocellular cancer (excluding fibrolamellar carcinoma)

- Part B3: Renal cell carcinoma (any histology)

- Part B4: Non-small cell lung cancer (squamous or non-squamous)

- Have at least 1 measurable lesion outside of the central nervous system (CNS) whose
presence is assessable using standard techniques by Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1.

- Availability of a tumor sample taken after progression on the most recent line of
systemic tumor therapy or willing to undergo a tumor biopsy pre-study treatment.

- Have a performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG)
scale in Part A and ≤ 1 on the ECOG scale in Part B.

- Have adequate organ function.

- Routine urinalysis showing ≤1+ protein or protein/creatinine ratio <0.5. For
proteinuria ≥2+ or urine protein/creatinine ratio ≥0.5, 24-hour urine must be
collected and the level must be <1 gram of protein in 24 hours for subject enrollment.

- Have discontinued all previous cancer therapies and any agents that have not received
regulatory approval for any indication, for at least 21 days or 5 halflives prior to
study enrollment, whichever is shorter, and recovered from the acute effects for
therapy.

- Have an estimated life expectancy, in the judgment of the investigator, that will
permit the participant to complete 8 weeks (2 cycles) of treatment.

- Males and females with reproductive potential: Must agree to use medically approved
contraceptive precautions during the study and for at least 3 months following the
last dose of study drug. Females with childbearing potential must have had a negative
serum pregnancy test 7 days before the first dose of study drug and must not be
breast-feeding.

Exclusion Criteria:

- Have serious pre-existing medical conditions (at the discretion of the investigator,
such as severe acute or chronic medical condition or laboratory abnormality that may
increase the risk associated with study participation).

- Have a history of hypertensive crisis or hypertensive encephalopathy or current poorly
controlled hypertension despite standard medical management.

- Participant has experienced any arterial thromboembolic event (ATE), including
myocardial infarction, unstable angina pectoris, cerebrovascular accident, or
transient ischemic attack, within 6 months prior to receiving study drugs.

- Have a history of deep vein thrombosis, pulmonary embolism, or any other significant
thromboembolic event during the 3 months prior to receiving study drugs.

- Are receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin,
or similar agents. Participants receiving prophylactic, low-dose anticoagulation
therapy are eligible provided that they are on low-molecular weight heparin or oral
factor Xa inhibitors.

- The participant is receiving chronic therapy with nonsteroidal anti-inflammatory drugs
or other antiplatelet agents. Aspirin use at doses up to 325 mg/day is permitted.

- Have significant bleeding disorders, vasculitis, or had a significant bleeding episode
from the gastrointestinal (GI) tract within 3 months prior to receiving study drugs.

- Have a history of GI perforation and/or fistulae within 6 months prior to receiving
study drugs.

- Have congestive heart failure (CHF) New York Heart Association class ≥3 or symptomatic
or poorly controlled cardiac arrhythmia.

- Have undergone major surgery within 28 days prior to receiving study drugs.

- Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days
prior to receiving study drugs.

- Have a known active fungal, bacterial, and/or known viral infection. Hepatocellular
cancer participants with chronic viral (B or C) hepatitis are eligible if they retain
adequate liver function.

- Have liver cirrhosis with a Child-Pugh Stage of B or C.

- Have symptomatic CNS malignancy (with the exception of medulloblastoma) or metastasis.

- Have corrected QT (QTc) interval of >470 milliseconds on screening electrocardiogram
(ECG).

- Have received previous treatment with ramucirumab or Emibetuzumab, except for
participants enrolled in cohort B1 (Gastric or GEJ adenocarcinoma) and B4 (non- small
cell lung cancer) who may have received previous ramucirumab treatment.

- Known hypersensitivity to any of the treatment components of ramucirumab or
Emibetuzumab.

- Have a second primary malignancy that, in the judgment of the investigator and
sponsor, may affect the interpretation of results.

- Are pregnant or breastfeeding.

- For Part B4 (non-small cell lung cancer) only:

- The participant has radiologically documented evidence of major blood vessel
invasion or encasement by cancer

- Participants with a history of gross hemoptysis within 2 months prior to study
treatment

- The participant has radiographic evidence of intratumor cavitation, regardless of
tumor histology